Akero Therapeutics (AKRO) Short Interest Ratio & Short Volume → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free AKRO Stock Alerts $21.02 -1.00 (-4.54%) (As of 05/8/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Akero Therapeutics Short Interest DataCurrent Short Volume8,180,000 sharesPrevious Short Volume7,840,000 sharesChange Vs. Previous Month+4.34%Dollar Volume Sold Short$177.67 millionShort Interest Ratio / Days to Cover6.0Last Record DateApril 15, 2024Outstanding Shares69,150,000 sharesPercentage of Shares Shorted11.83%Today's Trading Volume581,020 sharesAverage Trading Volume1,186,817 sharesToday's Volume Vs. Average49% Short Selling Akero Therapeutics ? Sign up to receive the latest short interest report for Akero Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAKRO Short Interest Over TimeAKRO Days to Cover Over TimeAKRO Percentage of Float Shorted Over Time Ad InvestorPlaceThe new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.Pay close attention to this important video Akero Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20248,180,000 shares $177.67 million +4.3%N/A6 $21.72 3/31/20247,840,000 shares $198.04 million -17.2%N/A5.8 $25.26 3/15/20249,470,000 shares $260.80 million +0.7%N/A6.9 $27.54 2/29/20249,400,000 shares $253.71 million +5.7%N/A6.9 $26.99 2/15/20248,890,000 shares $190.33 million +14.6%N/A8.2 $21.41 1/31/20247,760,000 shares $167.69 million +2.1%N/A7.2 $21.61 Get the Latest News and Ratings for AKRO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20247,600,000 shares $170.54 million +3.1%N/A6.3 $22.44 12/31/20237,370,000 shares $172.09 million +12.4%N/A3.8 $23.35 12/15/20236,560,000 shares $150.29 million +3.0%N/A3.4 $22.91 11/30/20236,370,000 shares $106.63 million +3.6%N/A3.4 $16.74 11/15/20236,150,000 shares $90.10 million +4.4%N/A3.3 $14.65 10/31/20235,890,000 shares $70.21 million -3.6%N/A3.3 $11.92 10/15/20236,110,000 shares $89.39 million +5.7%N/A3.8 $14.63 9/30/20235,780,000 shares $292.35 million -3.5%N/A4.7 $50.58 9/15/20235,990,000 shares $312.92 million -5.4%N/A8.2 $52.24 8/31/20236,330,000 shares $314.16 million +8.0%N/A9.3 $49.63 8/15/20235,860,000 shares $278.17 million +1.7%N/A8.9 $47.47 7/31/20235,760,000 shares $249.98 million +5.1%N/A8.6 $43.40 7/15/20235,480,000 shares $249.72 million +14.4%N/A8 $45.57 6/30/20234,790,000 shares $223.65 million +6.2%N/A6.7 $46.69 6/15/20234,510,000 shares $249.00 million -3.8%N/A6.2 $55.21 5/31/20234,690,000 shares $209.08 million +0.9%N/A6.8 $44.58 5/15/20234,650,000 shares $221.85 million No ChangeN/A7 $47.71 4/30/20234,650,000 shares $208.04 million -2.7%N/A7.5 $44.74 4/15/20234,780,000 shares $181.59 million +8.1%N/A7.8 $37.99 3/31/20234,420,000 shares $169.11 million +30.8%N/A7.4 $38.26 3/15/20233,380,000 shares $136.92 million -0.9%N/A5.2 $40.51 2/28/20233,410,000 shares $155.19 million -5.0%N/A4.7 $45.51 2/15/20233,590,000 shares $161.55 million -5.8%N/A4.9 $45.00 1/31/20233,810,000 shares $188.60 million -8.9%N/A5 $49.50 1/15/20234,180,000 shares $210.00 million -20.5%N/A5.5 $50.24 12/30/20225,260,000 shares $288.25 million +27.7%N/A6.9 $54.80 12/15/20224,120,000 shares $181.57 million -16.8%N/A5.2 $44.07 11/30/20224,950,000 shares $230.18 million +21.6%N/A3.2 $46.50 11/15/20224,070,000 shares $182.25 million -12.5%N/A2.7 $44.78 10/31/20224,650,000 shares $196.51 million +17.1%13.5%3.2 $42.26 10/15/20223,970,000 shares $152.85 million -24.7%11.8%2.8 $38.50 9/30/20225,270,000 shares $179.44 million -3.7%17.1%3.8 $34.05 9/15/20225,470,000 shares $145.12 million -11.5%17.8%4.3 $26.53 8/31/20226,180,000 shares $72.62 million +6.6%26.5%15.6 $11.75Fidelity, Bezos, Goldman Bet Big on Tiny Biotech (Ad)Are you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> AKRO Short Interest - Frequently Asked Questions What is Akero Therapeutics' current short interest? Short interest is the volume of Akero Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 8,180,000 shares of AKRO short. Learn More on Akero Therapeutics' current short interest. What is a good short interest ratio for Akero Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AKRO shares currently have a short interest ratio of 6.0. Learn More on Akero Therapeutics's short interest ratio. Which institutional investors are shorting Akero Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Akero Therapeutics: Concourse Financial Group Securities Inc., Simplex Trading LLC, and Kingdon Capital Management L.L.C.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Akero Therapeutics' short interest increasing or decreasing? Akero Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 8,180,000 shares, an increase of 4.3% from the previous total of 7,840,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Akero Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Akero Therapeutics: Protagonist Therapeutics, Inc. (6.00%), Morphic Holding, Inc. (12.48%), Dynavax Technologies Co. (14.17%), Xencor, Inc. (10.09%), Day One Biopharmaceuticals, Inc. (15.17%), Taro Pharmaceutical Industries Ltd. (0.58%), Kiniksa Pharmaceuticals, Ltd. (5.13%), Kura Oncology, Inc. (15.93%), Arcus Biosciences, Inc. (14.45%), ANI Pharmaceuticals, Inc. (1.01%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Akero Therapeutics stock? Short selling AKRO is an investing strategy that aims to generate trading profit from Akero Therapeutics as its price is falling. AKRO shares are trading down $0.66 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Akero Therapeutics? A short squeeze for Akero Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AKRO, which in turn drives the price of the stock up even further. How often is Akero Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKRO, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: PTGX Short Squeeze MORF Short Squeeze DVAX Short Squeeze XNCR Short Squeeze DAWN Short Squeeze TARO Short Squeeze KNSA Short Squeeze KURA Short Squeeze RCUS Short Squeeze ANIP Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AKRO) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings